Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

This is a phase 1/2 Study of VELCADE (bortezomib), Nipent (pentostatin), and Rituxan (rituximab) (VNR) in Subjects with Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma.

Condition or disease	Intervention/treatment	Phase
Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma	Drug: MTD of Velcade, Nipent and Rituxan established in Part 1	Phase 1; Phase 2

Detailed Description:

Number of Subjects: During the Phase 1 part of the study as many as 15 subjects may be enrolled, based on the dose escalation scheme; the actual number of subjects enrolled will depend on the dose level at which the maximum tolerated dose (MTD) is established.

During the Phase 2 part of the study, approximately 15 subjects will be enrolled in order to obtain a total 30 response-evaluable subjects.

Study Objectives:

The primary objectives of this study are:

• Assess the CR and ORR following treatment with VELCADE (bortezomib), Nipent (pentostatin) and Rituxan (rituximab) (VNR) in subjects with follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) who have relapsed or been refractory after receiving at least 1 prior therapy.

The secondary objectives of this study are to:

• Determine the MTD of VELCADE and Nipent in combination with Rituxan (VNR) in subjects with follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) who have relapsed or been refractory after receiving at least 1 prior therapy
• Evaluate the safety and tolerability of VNR
• Determine the time to response
• Determine duration of response
• Determine the time to progression (TTP)
• Determine the progression free survival (PFS) rate
• Determine the 1-year survival
• Determine overall survival (OS)

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	30 participants
Allocation:	Non-Randomized
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Phase 1/2 Study of VELCADE (Bortezomib), Nipent (Pentostatin), and Rituxan (Rituximab) (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma
Study Start Date :	May 2010
Estimated Primary Completion Date :	October 2014
Estimated Study Completion Date :	October 2014

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: Part 1: establish MTD; Part 1 consists of dosing to determine maximum tolerated dose (MTD) and dose limiting toxicity (DLT).	Drug: MTD of Velcade, Nipent and Rituxan established in Part 1; One of the following dose levels will be chosen and used in Part 2: (VAN1) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1; (VAN2) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1; (VBN1) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1; (VBN2) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1
Experimental: Part 2: The MTD from Part 1; During the Phase 2 part of the study, approximately 24 additional subjects will be enrolled in order to obtain a total of 30 response-evaluable subjects treated at the maximum tolerated dose.	Drug: MTD of Velcade, Nipent and Rituxan established in Part 1; One of the following dose levels will be chosen and used in Part 2: (VAN1) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1; (VAN2) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1; (VBN1) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1; (VBN2) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. CR following treatment with VELCADE(bortezomib)/Nipent(pentostatin/Rituxan (rituximab)(VNR) in subjects with follicular lymphoma(FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL)relapsed or refractory after at least 1 prior therapy [ Time Frame: up to 48 months ]
   Study Days 1, 4, 8, 11 of 6 cycles (up to 3 weeks each) and Days 63/126, then Study Months 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48
2. ORR following treatment with VELCADE(bortezomib)/Nipent(pentostatin/Rituxan (rituximab)(VNR) in subjects with follicular lymphoma(FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL)relapsed or refractory after at least 1 prior therapy [ Time Frame: up to 48 months ]
   Study Days 1, 4, 8, 11 of 6 cycles (up to 3 weeks each) and Days 63/126, then Study Months 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48

Secondary Outcome Measures :

1. Maximum Tolerated Dose [ Time Frame: Study Days 1, 4, 8, 11 of 6 cycles (up to 3 weeks each) and Days 63/126, then Study Months 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48 ]
   Number of participants with adverse events as a measure of safety and tolerability
2. Rate of progression of disease [ Time Frame: Study Days 1, 4, 8, 11 of 6 cycles (up to 3 weeks each) and Days 63/126, then Study Months 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48 ]
   Summary data on time to progression of disease of study subjects

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years to 85 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

1. Voluntary written informed consent.
2. Male or female subject 18 years of age and older
3. Karnofsky Performance Status (KPS) score of 50%. ECOG Performance Status score greater than 2.
4. Histologically confirmed follicular Grade 1-3a, marginal zone or mantle cell NHL.
5. Relapsed or progressive disease after at least 1 prior chemotherapy requiring treatment.
6. Bi-dimensionally measurable disease with at least 1 lesion 2 cm in a single dimension
7. Hematologic, hepatic, and renal function parameters.
8. Recovered fully from any significant toxicity associated with prior surgery, radiation treatments, chemotherapy, biological therapy, autologous bone marrow or stem cell transplant, or investigational drugs
9. Expected survival of 3 months
10. Accepted birth control methods during treatment and for 12 months after completion of treatment.

Exclusion Criteria:

1. Follicular lymphoma Grade 3b
2. History of allergy to any of the study medications, their analogues, murine proteins, or excipients in the various formulations
3. Grade 2 peripheral neuropathy or clinical examination within 14 days before enrollment
4. Serum creatinine 2.5 mg/dL within 14 days before enrollment.
5. Absolute neutrophil count (ANC) < 1,000/L, platelet count < 70,000/L within 14 days before enrollment
6. Aspartate transaminase (AST [SGOT]) and alanine transaminase (ALT/SGPT]) > 2 x the upper limit of normal (ULN), total bilirubin > 3 ULN
7. Rituxan refractory or refractory to anti-CD20 radioimmunotherapy (no response to prior Rituxan or prior Rituxan-containing regimen, or a response with a TTP of less than 6 months)
8. Cancer radiotherapy, biological therapy, or chemotherapy within 3 weeks prior to Study Day 1 (6 weeks if nitrosurea or mytomycin-C)
9. Prior lymphoma vaccine therapy within 12 months to Study Day 1
10. Prior antibody therapy for lymphoma (including radioimmunotherapy) within 6 months prior to Study Day 1
11. Autologous bone marrow or stem cell transplant within 6 months prior to Study Day 1
12. Known history of hepatitis or hepatic disease.
13. Presence of central nervous system (CNS) lymphoma
14. Known history of HIV infection or AIDS
15. Histologic transformation (Follicular or Marginal zone to diffuse large B cell lymphoma [DLBCL]
16. Presence of pleural or peritoneal effusion with positive cytology for lymphoma
17. Another primary malignancy requiring active treatment
18. Serious non-malignant disease (e.g., congestive heart failure [CHF], hydronephrosis); active uncontrolled bacterial, viral, or fungal infections; or other conditions (including psychiatric), which would compromise protocol objectives n the opinion of the Investigator and/or Sponsor
19. New York Heart Association Class III or IV (Appendix D) cardiac disease
20. Major surgery, other than diagnostic surgery, within 4 weeks prior to Study Day 1
21. Female subject who is pregnant or currently breast-feeding
22. Received other investigational drugs with 14 days before enrollment
23. Hypersensitivity to bortezomib, pentostatin, rituximab, boron or mannitol.

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

United States, Louisiana
LSU - Shreveport Health Sciences Center, Feist-Weiller Cancer Center
Shreveport, Louisiana, United States, 71103

Sponsors and Collaborators

Louisiana State University Health Sciences Center Shreveport

Millennium Pharmaceuticals, Inc.

Investigators

Principal Investigator:	Francesco Turturro, MD	LSUHSC-S

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Francesco Turturro, Professor of Medicine, Louisiana State University Health Sciences Center Shreveport
ClinicalTrials.gov Identifier:	NCT01460602 History of Changes
Other Study ID Numbers:	X05266
First Posted:	October 27, 2011
Last Update Posted:	October 27, 2011
Last Verified:	October 2011

Keywords provided by Francesco Turturro, Louisiana State University Health Sciences Center Shreveport:

Lymphoma; Follicular; Marginal Zone; Mantle Cell; Velcade; bortezomib	Nipent; pentastatin; Rituxan; rituximab; Turturro; Shreveport

Additional relevant MeSH terms:

Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, B-Cell, Marginal Zone; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Lymphoma, Non-Hodgkin	Lymphoma, B-Cell; Rituximab; Bortezomib; Pentostatin; Antineoplastic Agents; Immunologic Factors; Physiological Effects of Drugs; Antirheumatic Agents; Adenosine Deaminase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action